newsfilter
← Latest News
GlobeNewswire·

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BIOA
  • BioAge Labs announced the first participant was dosed in September 2026 for the Phase 2 QUELL-DME trial of BGE-102 for diabetic macular edema, with topline results expected in the second half of 2027.
  • The Phase 2 dose-ranging QUELL-CV trial for BGE-102 in obesity & elevated inflammation completed enrollment of ~160 participants, with topline data anticipated in Q4 2026.
  • The APJ agonist obesity program is on track for an IND submission by the end of 2026.
  • Third-quarter 2026 collaboration revenue was $0.3 million, a decrease from $2.1 million in the same period in 2025 due to a Novartis agreement amendment.
  • R&D expenses rose to $30.2 million in Q3 2026 from $18.5 million in 2025, driven by clinical trial & manufacturing costs for BGE-102 & increased personnel expenses.
  • General & administrative expenses increased to $7.5 million in Q3 2026 from $6.7 million in 2025, primarily due to higher stock-based compensation & consulting fees.
  • The company reported a net loss of $33.5 million ($0.73 per share) for Q3 2026 compared to a net loss of $20.2 million ($0.56 per share) in Q3 2025.
  • As of September 30, 2026, BioAge held approximately $352.3 million in cash, equivalents, & marketable securities, sufficient to fund operations through 2029.
  • BioAge advanced its AI-driven discovery collaboration with Deep Origin in October 2026, validating computationally identified hits against a novel target.
  • Strategic collaborations with Novartis (aging/exercise targets) & Lilly ExploR&D (metabolic aging antibodies) continued to progress.
Company
BioAge Labs, Inc.
Keywords
Nasdaq:BIOA, BioAge Labs, Inc.